

0% -10%

FUND OBJECTIVE

Seeks to achieve capital appreciation in the long term through investments in an international portfolio of Shariahcompliant equities and equity related securities.

| FUN | | |
|-----|--|--|
| | | |

| FUND DETAILS | | | | | |
|----------------------|---|--------------|--|--|--|
| Launch Date | 13 February 2015 | Domicile | Malaysia | | |
| Currency | Ringgit Malaysia | Launch Price | RM1.0000 | | |
| Units in Circulation | 3.629 million units (31 December 2018) | Fund Size | RM3.711 million (31 December 2018) | | |
| Unit NAV | RM1.0226 (31 December 2018) | Dealing | Daily (as per Bursa Malaysia trading day | | |
| Fund Manager | Aberdeen Islamic Asset Management Sdn. Bhd. | Target Fund | Aberdeen Islamic World Equity Fund | | |
| Benchmark | MSCI ACWI Islamic (Shariah) Index | Taxation | 8% of annual investment income | | |
| Risk Profile | Suitable for investors: Have a long term investment horizon Target capital appreciation Willing to take higher risk for potential higher gains | Fees | Sun Life Malaysia does not impose any fund management charge on Sun Life Malaysia Islamic World Equity Income Fund 1.75% pa fund management charge is applied on the target fund's NAV by Aberdeen Islamic Asset Management | | |

ASSET ALLOCATION OF THE TARGET FUND

90% - 100%

| SECTOR ALLOCATION OF THE TARGET FUND | | TOP HOLDINGS OF THE TARGET FUND | | |
|--------------------------------------|--------|---------------------------------|-------|--|
| Healthcare | 20.4% | Johnson & Johnson | 3.1% | |
| Consumer Staples | 19.2% | Novartis | 3.1% | |
| Industrials | 14.7% | Samsung Electronics | 3.0% | |
| Materials | 12.1% | Linde | 2.9% | |
| Energy | 9.8% | L'Oreal | 2.9% | |
| Information Technology | 8.7% | Chugai Pharmaceutical | 2.8% | |
| Consumer Discretionary | 7.7% | Henkel & KGaA | 2.8% | |
| Communication Services | 3.7% | Nestle | 2.6% | |
| Real Estate | 1.8% | Procter & Gamble Co | 2.6% | |
| Cash | 1.9% | Roche Holding | 2.5% | |
| Total | 100.0% | Total | 28.3% | |



PERFORMANCE RECORD

This fund feeds into Aberdeen Islamic World Equity Fund ("target fund") with the objective to achieve capital appreciation in the long term through investments in an international portfolio of Shariah-compliant equities and equity-related securities.

Table below shows the investment returns of Sun Life Malaysia Islamic World Equity Fund versus its benchmark as at 31 December 2018.

| % | YTD | 1M | 3M | 6M | 1-Year | 3-Year | Since Inception |
|-----------|-------|-------|--------|-------|--------|--------|--------------------|
| Fund* | -9.4% | -6.6% | -11.3% | -8.1% | -9.4% | 5.0% | 2.3% |
| Benchmark | -7.8% | -7.6% | -13.0% | -7.4% | -7.7% | 15.5% | 26.1% |

*Notice: Past performance of the fund is not an indication of its future performance which may differ. The fund performance is not guaranteed.

FUND MANAGER'S COMMENTS

- Global equities fell in most major currencies in December. The US S&P 500 index slipped into bear market territory
 after the US Federal Reserve withstood political pressure and raised rates for the fourth time in 2018. It also projected
 lower inflation and growth in the new year. The US Treasury Secretary's move to confirm, for no apparent reason, that
 Wall Street banks had sufficient liquidity further spooked investors.
- In a sign that Chinese policymakers remained concerned about a weakening economy, the People's Bank of China announced fresh fiscal and monetary stimulus measures. Profits fell at Chinese industrial companies for the first time in nearly three years. In Europe, Rome and Brussels ended a two-month stand-off over Italy's 2019 budget after agreeing to a narrower deficit. Elsewhere, international oil prices reached a 15-month low, as swelling US shale output overshadowed planned output curbs by producers led by Saudi Arabia and Russia.
- In corporate news, Swiss drugmaker Novartis is exploring new funding models with the global reinsurance industry for expensive personalised therapies. These, including specialised cell and gene treatments, represent future growth drivers for pharmaceutical companies.
- Speciality chemicals group Croda International acquired Danish pharmaceutical business Brenntag Biosector, which serves the human and veterinary vaccine market, for €72 million in a cash deal. Meanwhile, health products conglomerate Johnson & Johnson was pressured by news reports that it knew for decades about the presence of cancer-causing asbestos in its products. The company refuted the suggestion that it knew or hid information about its product safety.
- We initiated cocoa and chocolate maker Barry Callebaut, which benefits from the global outsourcing trend and growing demand for premium products, and beauty and cosmetics giant Estee Lauder, which has a solid global footprint and an attractive portfolio of brands. We added to Canadian fertiliser company Nutrien, as it has strengthened its balance sheet following the sale of its stake in SQM and effectively cut costs post-merger. We also topped up oilfield services provider Schlumberger following its recent share-price weakness.
- Against these, we divested South Korean beauty and cosmetics firm AmorePacific as our investment thesis failed to
 play out. While management is optimistic of a turnaround, we think there could be significant execution risk. Its
 prospects were also dampened by diminishing competitive advantage in Korea and intensifying competition in China.
 We also exited mining giant BHP Billiton as it enters a re-investment cycle, and Japanese snack food maker Calbee
 as it struggled to parlay its domestic success overseas, which has weighed on long-term opportunities. We trimmed
 Japan's Chugai Pharmaceutical after its recent share-price strength.

Source : Aberdeen Islamic Asset Management Sdn. Bhd. Date : 31 December 2018

Disclaimer:

The benchmark performance is not a guide to future performances which may differ. The performance of the fund is not guaranteed. The value of the fund will fluctuate and may fall below the amount of premiums paid and the fund value depends on the actual performance of the underlying investment. This material is for information purposes only and is subject to change at any time without notice. Sun Life Malaysia does not guarantee its accuracy, completeness, correctness or timeliness for any purpose or reason. This information should not be considered as advice or recommendation in relation to your account or particular investment objectives, financial situation or needs. You may not revise, transform, or build upon this material without prior written consent of Sun Life Malaysia. Before acting on any information you should seek independent financial advice.